[Radioiodine treatment of Graves' disease --for its wider indication and application in Japan].
Radioiodine treatment has been well established as an effective and safe therapeutic modality for Graves' disease. To promote more efficient use of this treatment in Japan, a working group has been organized in the Japan Thyroid Association and preparation of guidelines for its clinical use is under way. The treatment using upto 13.5 mCi of I-131 is feasible on out-patient basis. In comparison to the antithyroid drug treatment, the treatment has no side effects, brings in good control of hyperthyroidism and decrease the size of goiter. It is contraindicated in pregnant and lactating women. Patients treated should be carefully monitored for the possible worsening of ophthalmopathy and neonatal Graves' disease. Recent studies revealed the cost-effectiveness of the treatment. Its application to autonomously functioning thyroid nodules and toxic multinodular goiters is also discussed.
Konishi
Junji
J
Kyoto University.
D000075202:Contraindications; D003362:Cost-Benefit Analysis; D005260:Female; D006111:Graves Disease / Q000532:radiotherapy*; D049970:Graves Ophthalmopathy / Q000209:etiology; D006801:Humans; D007231:Infant, Newborn; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D007564:Japan; D017410:Practice Guidelines as Topic; D011247:Pregnancy
D007457:Iodine Radioisotopes